Chinese Medical Journal (Jul 2024)

Role of triggering receptor expressed on myeloid cells-1 in kidney diseases: A biomarker and potential therapeutic target

  • Yuxi Fan,
  • Ye Xu,
  • Zhi Huo,
  • Hedong Zhang,
  • Longkai Peng,
  • Xin Jiang,
  • Angus W. Thomson,
  • Helong Dai,
  • Sihan Zhou,
  • Xiuyuan Hao

DOI
https://doi.org/10.1097/CM9.0000000000003197
Journal volume & issue
Vol. 137, no. 14
pp. 1663 – 1673

Abstract

Read online

Abstract. Triggering receptor expressed on myeloid cells-1 (TREM-1) is a member of the immunoglobulin superfamily. As an amplifier of the inflammatory response, TREM-1 is mainly involved in the production of inflammatory mediators and the regulation of cell survival. TREM-1 has been studied in infectious diseases and more recently in non-infectious disorders. More and more studies have shown that TREM-1 plays an important pathogenic role in kidney diseases. There is evidence that TREM-1 can not only be used as a biomarker for diagnosis of disease but also as a potential therapeutic target to guide the development of novel therapeutic agents for kidney disease. This review summarized molecular biology of TREM-1 and its signaling pathways as well as immune response in the progress of acute kidney injury, renal fibrosis, diabetic nephropathy, immune nephropathy, and renal cell carcinoma.